Chart-Typ:
Zeitraum:
| Novavax, Inc.: Novavax Reports First Quarter 2026 Financial Results and Operational Highlights | Total revenue of $140 million in the first quarter of 2026
Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M® in two infectious... ► Artikel lesen |
| FOMO an der Wall Street: Novavax meldet überraschenden Gewinn - Aktie schießt zweistellig hoch | © Foto: picture alliance / Ulrich Baumgarten | Ulrich BaumgartenEin Ergebnis, das niemand erwartet hatte, gepaart mit neuen Big-Pharma-Deals: Novavax sorgt für FOMO an der Wall Street. Wie lange hält... ► Artikel lesen |
| Novavax, Inc.: Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights | Pfizer agreement announced in January 2026 for non-exclusive license to utilize Matrix-M® in two infectious disease areas
Multiple Material Transfer Agreements... ► Artikel lesen |
| Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen |
| Morning Market Movers: Super Micro Computer, Bimergen Energy, Palatin Technologies, Intellicheck See Big Swings | HONG KONG (dpa-AFX) - At 7:40 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen |
| Palatin Technologies, Inc.: Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update | Advancing differentiated MC4R-based obesity programs into clinical development
Melanocortin-based obesity therapies targeting rare MC4R pathway disorders with... ► Artikel lesen |
| Ocugen Provides Business Update with First Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p About 20%... ► Artikel lesen |
| Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease | GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by mid-2027OCU410ST represents a potential first-in-class, one-time... ► Artikel lesen |
| Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (pPotential 2X treatment benefit compared to 15% and 22% reductions... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RYOJBABA CO LTD finden Sie auf Wallstreet Online.